Drug profile · INN
finerenone
KERENDIA
finerenone (KERENDIA) is a mineralocorticoid receptor antagonist. Associated with Bayer Australia Ltd. Route of administration: film coated. Current US regulatory status: approved.
Drug details — finerenone
- US status
- approved
- Class
- Cardiovascular system (C09)
- Route
- FILM COATED
- Patents
- 1
- Programs
- 19
- Data quality
- 0.84
Quick answer
finerenone (KERENDIA) is a mineralocorticoid receptor antagonist. Associated with Bayer Australia Ltd. Route of administration: film coated. Current US regulatory status: approved.
Key facts
Mechanism of action
Mineralocorticoid receptor antagonist
Primary target: Mineralocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is finerenone?
finerenone (KERENDIA) is a mineralocorticoid receptor antagonist. Associated with Bayer Australia Ltd. Route of administration: film coated. Current US regulatory status: approved.
What is the brand name for finerenone?
KERENDIA is a marketed brand name for finerenone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of finerenone?
finerenone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.